(Date:11/19/2009)...FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), an...r to its shareholders, discussing the Company,s ac...ceuticals Holdings, Inc. (CHBP), an integrated bio...blic of China. The merger gives NeoStem a controll... Ltd., CHBP,s primary operating subsidiary and a p...
(Date:11/19/2009)...ber 19 MONITORING FORCE GmbH,annou...libanserin in the,indication treatment-relevant le...or orphan drug status designation with the Europea...esia is a complication of the mainstay,treatment i...e of those,affected, since it may be disabling for...
(Date:11/19/2009)...e Synthesis Companies Form International Gene Synt...es in Risk Reduction ,Five Member Companies Repr...ity , (PRWEB) November 19...ynthesis companies today announced agreement that ...mote biosecurity in the gene synthesis industry. ...
(Date:11/18/2009)...ire/ -- Marrone Bio Innovations (MBI), a leader in...of effective and environmentally responsible pest ...med an IC20 company by the Investors, Circle, the ...nvesting group. ,, Companies named to the IC20 ...for all stakeholders, including investors, the env...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Marrone Bio Innovations Named an IC20 Company 2...- Oncothyreon Inc. (NASDAQ:,ONTY) (TSX: ONY) (the ...o,focus the Company,s resources on the clinical de...lopment and manufacturing of Stimuvax(R).,Oncothyr...opment of PX-12,beyond the ongoing trials. The pri...yreon,s efforts and available resources on those p...
...ics,Inc. (Nasdaq: CVTX ) announced today that the... 1 trial of CVT-3619, a novel oral compound for po... U.S. Food and Drug,Administration recently accept...ion for CVT-3619, a partial A1 adenosine receptor ...ty and pharmacokinetic profile,of CVT-3619 in heal...
...rdue patents; Purdue licenses limited sa..., Conn., Sept. 2 Purdue Pharma L.P. of,Stamford, ...ssouri have,agreed to end the OxyContin(R) (oxycod...ement lawsuit between them in the United States Di...., According to the agreement, Mallinckrodt ackno...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2Cleland’s Reagent, ULTROL® Grade from Calbiochem
...icroarray is specifically designed for location an... pairing chromatin immunoprecipitation (ChIP) with... hybridization and reliable binding data with grea... In addition, Agilent provides flexibility by offe...
...mes has allowed the development of the S. enterica...rica Typhimurium (strain LT2) genome consists of a...a plasmid, pSLT (93,939 bp; 107 ORFs). These ORFme...y all putative open reading frames (ORFs) in S. en...
...system, offers fast and reliable batch processing ...lution , SAFIRE monochromator reader , GENios fami...s of Laser Scanners , Powerwash 384 ,By supporti...s, Connect offers researchers increased throughput...
Biology Products: